TY  - JOUR
AB  - Dual-PPAR-?/? agonist has the dual potentials to improve insulin resistance (IR) and hepatic steatosis associated with obesity. This study aimed to investigate whether dehydroabietic acid (DA), a naturally occurred compound, can bind to and activate both PPAR-? and PPAR-? to ameliorate IR and hepatic steatosis in high-fat diet (HFD)-fed mice.. We found that DA formed stable hydrogen bonds with the ligand-binding domains of PPAR-? and PPAR-?. DA treatment also promoted 3T3-L1 differentiation via PPAR-? activation, and mitochondrial oxygen consumption in HL7702 cells via PPAR-? activation. In HFD-fed mice, DA treatment alleviated glucose intolerance and IR, and reduced hepatic steatosis, liver injury markers (ALT, AST), and lipid accumulation, and promoted mRNA expression of PPAR-? and PPAR-? signaling elements involved in IR and lipid metabolism in vivo and in vitro, and inhibited mRNA expression of pro-inflammatory factors. Therefore, DA is a dual-PPAR-?/? and PPAR-? partial agonist, which can attenuate IR and hepatic steatosis induced by HFD-consumption in mice.
AU  - Xie, Z
AU  - Gao, G
AU  - Wang, H
AU  - Li, E
AU  - Yuan, Y
AU  - Xu, J
AU  - Zhang, Z
AU  - Wang, P
AU  - Fu, Y
AU  - Zeng, H
AU  - Song, J
AU  - Hölscher, C
AU  - Chen, H
DA  - 2020/07/01
DO  - 10.1016/j.biopha.2020.110155
JO  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
PB  - ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PY  - 2020/07/01
TI  - Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-? and PPAR-?.
VL  - 127
Y1  - 2020/07/01
Y2  - 2026/05/27
ER  -